Mereo BioPharma Group plc (MREO)
NASDAQ$2.62
Market Cap
$81.08M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
717 of 924
Rank in Industry
409 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
MREO Insider Trading Activity
MREO Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $3,079,680 | 22 | 100 |
Related Transactions
| Lewicki John A. | Chief Scientific Officer | 0 | $0 | 4 | $153,904 | $-153,904 |
| Fox Christine Ann | Chief Financial Officer | 0 | $0 | 4 | $269,569 | $-269,569 |
| Sermon Charles | General Counsel | 0 | $0 | 4 | $294,728 | $-294,728 |
| PAKIANATHAN DEEPIKA | director | 0 | $0 | 1 | $466,210 | $-466,210 |
| Scots-Knight Denise | Chief Executive Officer | 0 | $0 | 4 | $844,909 | $-844,909 |
| Hughes-Wilson Alexandra | See Remarks | 0 | $0 | 5 | $1.05M | $-1.05M |
About Mereo BioPharma Group plc
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 …
Insider Activity of Mereo BioPharma Group plc
Over the last 12 months, insiders at Mereo BioPharma Group plc have bought $0 and sold $3.08M worth of Mereo BioPharma Group plc stock.
On average, over the past 5 years, insiders at Mereo BioPharma Group plc have bought $0 and sold $3.08M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
List of Insider Buy and Sell Transactions, Mereo BioPharma Group plc
| 2024-09-13 | Sale | Scots-Knight Denise | Chief Executive Officer | 60,046 0.0454% | $4.22 | $253,454 | -16.59% | |
| 2024-09-13 | Sale | Sermon Charles | General Counsel | 20,946 0.0158% | $4.22 | $88,413 | -16.59% | |
| 2024-09-13 | Sale | Fox Christine Ann | Chief Financial Officer | 19,158 0.0145% | $4.22 | $80,866 | -16.59% | |
| 2024-09-13 | Sale | Lewicki John A. | Chief Scientific Officer | 10,937 0.0083% | $4.22 | $46,165 | -16.59% | |
| 2024-09-13 | Sale | Hughes-Wilson Alexandra | See Remarks | 100,312 0.0759% | $4.22 | $423,417 | -16.59% | |
| 2024-09-12 | Sale | Scots-Knight Denise | Chief Executive Officer | 28,611 0.0229% | $4.47 | $127,968 | -18.45% | |
| 2024-09-12 | Sale | Sermon Charles | General Counsel | 9,980 0.008% | $4.47 | $44,638 | -18.45% | |
| 2024-09-12 | Sale | Hughes-Wilson Alexandra | See Remarks | 47,798 0.0383% | $4.47 | $213,786 | -18.45% | |
| 2024-09-12 | Sale | Fox Christine Ann | Chief Financial Officer | 9,128 0.0073% | $4.47 | $40,827 | -18.45% | |
| 2024-09-12 | Sale | Lewicki John A. | Chief Scientific Officer | 5,212 0.0042% | $4.47 | $23,312 | -18.45% | |
| 2024-08-22 | Sale | PAKIANATHAN DEEPIKA | director | 105,244 0.0836% | $4.43 | $466,210 | -17.29% | |
| 2024-06-26 | Sale | Scots-Knight Denise | Chief Executive Officer | 92,273 0.0561% | $3.39 | $313,101 | +9.17% | |
| 2024-06-26 | Sale | Sermon Charles | General Counsel | 32,187 0.0196% | $3.39 | $109,217 | +9.17% | |
| 2024-06-26 | Sale | Fox Christine Ann | Chief Financial Officer | 29,439 0.0179% | $3.39 | $99,892 | +9.17% | |
| 2024-06-26 | Sale | Lewicki John A. | Chief Scientific Officer | 16,808 0.0102% | $3.39 | $57,033 | +9.17% | |
| 2024-06-26 | Sale | Hughes-Wilson Alexandra | See Remarks | 22,968 0.014% | $3.39 | $77,935 | +9.17% | |
| 2024-06-25 | Sale | Scots-Knight Denise | Chief Executive Officer | 40,712 0.027% | $3.69 | $150,386 | +8.71% | |
| 2024-06-25 | Sale | Sermon Charles | General Counsel | 14,202 0.0094% | $3.69 | $52,461 | +8.71% | |
| 2024-06-25 | Sale | Fox Christine Ann | Chief Financial Officer | 12,990 0.0086% | $3.69 | $47,984 | +8.71% | |
| 2024-06-25 | Sale | Lewicki John A. | Chief Scientific Officer | 7,416 0.0049% | $3.69 | $27,394 | +8.71% |
Total: 22
*Gray background shows transactions not older than one year
MREO Institutional Investors: Active Positions
| Increased Positions | 39 | +40.63% | 15M | +13.9% |
| Decreased Positions | 35 | -36.46% | 5M | -5% |
| New Positions | 20 | New | 7M | New |
| Sold Out Positions | 9 | Sold Out | 318,209 | Sold Out |
| Total Postitions | 100 | +4.17% | 115M | +8.89% |
MREO Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Janus Henderson Group Plc | $41,094.00 | 2.21% | 17.12M | +5M | +38.69% | 2024-12-31 |
| Rubric Capital Management Lp | $36,738.00 | 1.97% | 15.31M | 0 | 0% | 2024-12-31 |
| Rock Springs Capital Management Lp | $23,038.00 | 1.24% | 9.6M | +65,000 | +0.68% | 2024-12-31 |
| Adage Capital Partners Gp, L.L.C. | $20,916.00 | 1.12% | 8.72M | -1M | -10.29% | 2024-12-31 |
| Mangrove Partners Im, Llc | $20,728.00 | 1.11% | 8.64M | -93,235 | -1.07% | 2024-12-31 |
| Deerfield Management Company, L.P. (Series C) | $16,105.00 | 0.87% | 6.71M | 0 | 0% | 2024-12-31 |
| Frazier Life Sciences Management, L.P. | $12,235.00 | 0.66% | 5.1M | 0 | 0% | 2024-12-31 |
| Alkeon Capital Management Llc | $11,275.00 | 0.61% | 4.7M | 0 | 0% | 2024-12-31 |
| 683 Capital Management, Llc | $10,920.00 | 0.59% | 4.55M | -299,800 | -6.18% | 2024-12-31 |
| Millennium Management Llc | $9,517.00 | 0.51% | 3.97M | -1M | -26.49% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.